ArticleBulletin of the World Health Organization2014
Impact of BRICS' investment in vaccine development on the global vaccine market.
Article in Bulletin of the World Health Organization, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Progress, impacts and lessons from market shaping in the past decade: a systematic review.Frontiers in public health · 2025Pooled it
- On the momentum toward vaccine self-sufficiency in the BRICS: an integrative review of the role of pharmaceutical entrepreneurship and innovation.Frontiers in public health · 2023Pooled it
- Biotechnological sovereignty is not a mere nationalist concept, it is a necessity for Colombia and Latin America.Cadernos de saude publica · 2024Article
- Time trends in the burden of autoimmune diseases across the BRICS: an age-period-cohort analysis for the GBD 2019.RMD open · 2023Article
- [Technological and productive trajectory of the human vaccine industry in Mexico: post-Covid-19 perspectives].Revista de salud publica (Bogota, Colombia) · 2023Article
- Vaccine technology transfer in a global health crisis: Actors, capabilities, and institutions.Research policy · 2023Article
- Health disparity and mortality trends of infectious diseases in BRICS from 1990 to 2019.Journal of global health · 2022Article
- Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities.Vaccine · 2021Article
- Vaccine Prices: A Systematic Review of Literature.Vaccines · 2020Review
- Studying Public Perception about Vaccination: A Sentiment Analysis of Tweets.International journal of environmental research and public health · 2020Article
- Vaccine Production in Africa: A Feasible Business Model for Capacity Building and Sustainable New Vaccine Introduction.Frontiers in public health · 2019Article
- Challenges for nationwide vaccine delivery in African countries.International journal of health economics and management · 2018Review
- Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.Frontiers in immunology · 2018Review
- Review
- Review
- China's role as a global health donor in Africa: what can we learn from studying under reported resource flows?Globalization and health · 2014Article
- Essential drugs production in Brazil, Russia, India, China and South Africa (BRICS): opportunities and challenges.International journal of health policy and management · 2014Review
- BRICS and global health.Bulletin of the World Health Organization · 2014Article
- Uric acid and the vaccine adjuvant activity of aluminium (oxy)hydroxide nanoparticles.Journal of drug targetingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brazil, the Russian Federation, India, China and South Africa--the countries known as BRICS--have made considerable progress in vaccine production, regulation and development over the past 20 years. In 1993, all five countries were producing vaccines but the processes used were outdated and non-standardized, there was little relevant research and there was negligible international recognition of the products. By 2014, all five countries had strong initiatives for the development of vaccine technology and had greatly improved their national regulatory capacity. South Africa was then the only BRICS country that was not completely producing vaccines. South Africa is now in the process of re-establishing its own vaccine production and passing beyond the stage of simply importing, formulating and filling vaccine bulks. Changes in the public sector's price per dose of selected vaccines, the global market share represented by products from specific manufacturers, and the attractiveness, for multinational companies, of partnership and investment opportunities in BRICS companies have all been analysed. The results indicate that the BRICS countries have had a major impact on vaccine price and availability, with much of that impact attributable to the output of Indian vaccine manufacturers. China is expected to have a greater impact soon, given the anticipated development of Chinese vaccine manufacturers in the near future. BRICS' accomplishments in the field of vaccine development are expected to reshape the global vaccine market and accelerate access to vaccines in the developing world. The challenge is to turn these expectations into strategic actions and practical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.